$391 Million is the total value of JOHNSON & JOHNSON's 22 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporationads | $89,605,000 | +51.3% | 1,629,173 | 0.0% | 22.89% | +104.5% | |
| FATE | Fate Therapeutics, Inc. | $83,733,000 | -36.1% | 3,379,064 | 0.0% | 21.39% | -13.6% | |
| ARWR | Arrowhead Pharmaceuticals, Inc. | $44,395,000 | -23.4% | 1,260,869 | 0.0% | 11.34% | +3.5% | |
| Procept BioRobotics Corporation | $33,294,000 | -6.6% | 1,018,478 | 0.0% | 8.50% | +26.2% | ||
| MGTX | MeiraGTx Holdings plc | $21,942,000 | -45.3% | 2,898,550 | 0.0% | 5.60% | -26.1% | |
| CVRX | CVRx, Inc. | $21,008,000 | +0.3% | 3,495,575 | 0.0% | 5.37% | +35.6% | |
| XNCR | Xencor, Inc. | $20,474,000 | +2.6% | 748,062 | 0.0% | 5.23% | +38.6% | |
| PTGX | Protagonist Therapeutics Inc. | $19,373,000 | -66.6% | 2,449,183 | 0.0% | 4.95% | -54.9% | |
| Cue Health, Inc. | $17,756,000 | -50.4% | 5,548,864 | 0.0% | 4.54% | -33.0% | ||
| ACET | Adicet Bio, Inc. | $10,643,000 | -26.9% | 728,944 | 0.0% | 2.72% | -1.2% | |
| FUSN | Fusion Pharmaceuticals Inc. | $9,140,000 | -68.0% | 3,670,516 | 0.0% | 2.34% | -56.7% | |
| PNT | Point Biopharma Global Inc. | $6,810,000 | -14.6% | 1,000,000 | 0.0% | 1.74% | +15.5% | |
| VOR | Vor Biopharma, Inc. | $5,341,000 | -17.7% | 1,074,658 | 0.0% | 1.36% | +11.2% | |
| NNOX | Nano-X Imaging Ltd. | $2,174,000 | +4.2% | 192,429 | 0.0% | 0.56% | +40.9% | |
| ALDX | Aldeyra Therapeutics, Inc. | $1,575,000 | -10.3% | 394,834 | 0.0% | 0.40% | +21.1% | |
| PHGE | BiomX Inc. | $1,557,000 | -62.2% | 2,133,402 | 0.0% | 0.40% | -48.8% | |
| SomaLogic, Inc. | $1,270,000 | -43.7% | 281,052 | 0.0% | 0.32% | -23.9% | ||
| PHAS | PhaseBio Pharmaceuticals, Inc. | $964,000 | -54.5% | 1,607,044 | 0.0% | 0.25% | -38.7% | |
| TCON | Tracon Pharmaceuticals, Inc. | $168,000 | -24.0% | 84,003 | 0.0% | 0.04% | +2.4% | |
| CBIO | Catalyst Biosciences, Inc. | $119,000 | +170.5% | 66,951 | 0.0% | 0.03% | +275.0% | |
| GRAY | Graybug Vision, Inc. | $54,000 | -11.5% | 49,547 | 0.0% | 0.01% | +16.7% | |
| SENS | Senseonics Holdings, Inc. | $56,000 | -48.1% | 54,621 | 0.0% | 0.01% | -30.0% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEGEND BIOTECH CORPORATION | 9 | Q3 2023 | 25.6% |
| FATE THERAPEUTICS, INC. | 9 | Q3 2023 | 24.8% |
| PROTAGONIST THERAPEUTICS INC. | 9 | Q3 2023 | 21.0% |
| CVRX, INC. | 9 | Q3 2023 | 19.5% |
| MEIRAGTX HOLDINGS PLC | 9 | Q3 2023 | 13.9% |
| Arrowhead Pharmaceuticals, Inc. | 9 | Q3 2023 | 24.6% |
| PROCEPT BIOROBOTICS CORPORATION | 9 | Q3 2023 | 10.5% |
| CUE HEALTH, INC. | 9 | Q3 2023 | 8.5% |
| FUSION PHARMACEUTICALS INC. | 9 | Q3 2023 | 5.4% |
| POINT BIOPHARMA GLOBAL INC. | 9 | Q3 2023 | 2.8% |
View JOHNSON & JOHNSON's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Fusion Pharmaceuticals Inc. | January 27, 2023 | 3,670,516 | 8.2% |
| Protagonist Therapeutics, Inc | January 11, 2023 | 2,449,183 | 5.0% |
| MeiraGTx Holdings plc | November 14, 2022 | 6,641,064 | 13.7% |
| PhaseBio Pharmaceuticals Inc | February 01, 2022 | 1,607,044 | 3.3% |
| Provention Bio, Inc. | January 17, 2020 | 1,124,973 | 2.4% |
| ADURO BIOTECH, INC. | January 22, 2019 | 3,906,207 | 4.9% |
| Aldeyra Therapeutics, Inc. | January 22, 2019 | 1,050,292 | 4.0% |
| GI DYNAMICS, INC. | January 22, 2019 | 565,569 | 3.7% |
| MACROGENICS INC | January 22, 2019 | 1,923,077 | 4.6% |
| Merus N.V. | January 22, 2019 | ? | ? |
View JOHNSON & JOHNSON's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 8-K/A | 2024-04-16 |
| 8-K | 2024-04-16 |
| 3 | 2024-04-10 |
| SC 13G | 2024-04-10 |
| DFAN14A | 2024-04-05 |
| PX14A6G | 2024-03-27 |
| 144 | 2024-03-13 |
| 4 | 2024-03-13 |
| ARS | 2024-03-13 |
| DEF 14A | 2024-03-13 |
View JOHNSON & JOHNSON's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Annual reports (10-K)
- Quarterly reports (10-Q)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.